Funding
← Back to your selection

Qiming Venture Partners

Activity from announced rounds

Activity in this selectionOct 9, 2026 · Asia · Jan 1, 2026
Rounds participated in
8
Confirmed lead rounds
—
8 roles undisclosed
New companies
7
First participation on record · 1 follow-on
Funding in participating rounds
$693M
8 disclosed · full round size, not this investor’s share

By stage

Series A3
Undisclosed3
Series B1
Series C+1

By primary sector

Biotech5
Healthtech2
AI1

By country

China7
Singapore1

Rounds

8 in this selection
Vivacta Biotechnology

Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases

$50MSeries A+
Role not disclosed
Pulnovo Medical

Develops interventional therapies for pulmonary hypertension and heart failure

$100MStrategic
Role not disclosed
Syneron Bio

Develops intelligent platform-driven macrocyclic peptide drug discovery

$150MSeries B
Role not disclosed
StairMed

Develops minimally invasive implantable brain-machine interfaces (BMI) for neurological diseases

CN¥500MStrategic
Role not disclosed
ShengShu Technology

Develops multimodal foundation models for video generation and AI productivity

CN¥600MSeries A
Role not disclosed
Oricell Therapeutics

Develops next-generation cell therapies for oncology and immunology

$70MSeries C1
Role not disclosed